Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL): A Patient Guide

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are biologically the same disease, involving the same type of mature, abnormal white blood cells called B-lymphocytes ^[1]. The different names simply describe where those cells are primarily located when the disease is discovered. If the abnormal cells are found mostly in the bloodstream and bone marrow, it is called CLL; if they are found primarily in the lymph nodes, it is called SLL ^[1][2]. Because they are two versions of the same condition, they are managed and treated using the same clinical strategies ^[2].

For most people, CLL and SLL are indolent, meaning they grow very slowly and may not cause any symptoms for many years ^[3][4]. Because of this slow behavior, the global standard of care for someone who feels well is a strategy called active surveillance, often known as “watch and wait” ^[5]. Research has consistently shown that starting treatment early, before symptoms appear, does not improve overall survival and may expose patients to unnecessary side effects ^[5][6]. Instead, doctors monitor your blood counts and physical health during regular check-ups, reserving treatment for the point when symptoms, dropping blood counts, or disease biology truly require intervention ^[7]. The prognosis and timeline for treatment depend heavily on your age, other health conditions, and the genetic makeup of the disease.

When the time eventually comes to start treatment, the decision is guided by a specific set of genetic tests that look at the “blueprint” of the cancer cells ^[8]. These tests, including FISH, TP53 sequencing, and IGHV mutation status, allow your care team to understand how the disease is likely to behave and which medications will be most effective ^[8][9]. These markers are essential because they help doctors move away from a “one-size-fits-all” approach and tailor treatment to your specific biological profile ^[10].

In recent years, the treatment of CLL/SLL has undergone a revolution, shifting away from traditional chemotherapy toward targeted therapies ^[11]. These modern medicines—primarily BTK inhibitors and BCL-2 inhibitors—work by blocking the specific proteins that allow the cancer cells to survive ^[6][11]. While a diagnosis of CLL or SLL is a significant life event, the slow-growing nature of the disease and the availability of these advanced treatments mean that many people live full, active lives for many years after their diagnosis ^[12].

Common Terms Used in This Guide

• ALC (Absolute Lymphocyte Count): The total number of lymphocyte white blood cells in your blood.
• B-cells (B-lymphocytes): A type of white blood cell that normally fights infection, but grows out of control in CLL/SLL.
• BTK and BCL-2: Specific proteins inside cells that keep them alive. Targeted drugs block these proteins.
• FISH, TP53, IGHV: Specialized genetic tests that look at the DNA of your cancer cells to guide treatment choices.
• TLS (Tumor Lysis Syndrome): A dangerous condition where cancer cells break down too quickly during treatment, overwhelming the kidneys.